Companies
/Healthcare
Apyx Medical Inc
$2.63
▲ $0.07 (+2.84%) today
Markets open · 10:35am ET
24/7 Wall St. View
APYX at a Glance
Valuation
- Market cap
- $107.8M
Profitability
- Revenue (TTM)
- $58.4M
- Profit margin
- -14.8%
- EPS (TTM)
- $-0.20
Price
- 52-week range
- $2 – $5
- Street target
- $6.50
Earnings
- Next report
- Nov 5, 2026
- Q2 2026 EPS
- $-0.07
- vs. $-0.08 est.
- +14.6%
Headquartered in Clearwater, FL Fiscal year ends December NASDAQ: APYX apyxmedical.com
About Apyx Medical
Apyx Medical Corporation is a surgical aesthetics company focused on body contouring and tissue contraction technologies. Its core products include the Renuvion and J-Plasma helium plasma platforms, which deliver controlled heat to tissue for cosmetic and hospital surgical applications, and the AYON Body Contouring System, an FDA-cleared all-in-one platform that integrates fat removal, closed loop contouring, electrosurgical capabilities, and Renuvion tissue contraction for comprehensive body contouring procedures. The AYON system, launched commercially in Q3 2025, is designed for surgeons performing aesthetic body contouring surgeries. The company also generates revenue through OEM agreements, leveraging its expertise in unique waveforms to supply other medical device manufacturers, though this segment is being de-emphasized over time. Renuvion and J-Plasma efficacy is supported by more than 90 clinical documents. The company trades on NASDAQ under the ticker APYX. Updated
Revenue by Segment · Q2 2026
- Surgical Aesthetics89%
- OEM11%
Frequently Asked Questions
What does Apyx Medical do?
Apyx Medical Corporation is a surgical aesthetics company focused on body contouring and tissue contraction technologies.
What is the APYX stock price target?
The Wall Street consensus 12-month price target for APYX is $6.50.